7,681 reports of this reaction
1.6% of all SECUKINUMAB reports
#11 most reported adverse reaction
DIARRHOEA is the #11 most commonly reported adverse reaction for SECUKINUMAB, manufactured by Novartis Pharmaceuticals Corporation. There are 7,681 FDA adverse event reports linking SECUKINUMAB to DIARRHOEA. This represents approximately 1.6% of all 482,303 adverse event reports for this drug.
SECUKINUMAB has an overall safety score of 65 out of 100. Patients taking SECUKINUMAB who experience diarrhoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIARRHOEA is a less commonly reported adverse event for SECUKINUMAB, but still significant enough to appear in the safety profile.
In addition to diarrhoea, the following adverse reactions have been reported for SECUKINUMAB:
The following drugs have also been linked to diarrhoea in FDA adverse event reports:
DIARRHOEA has been reported as an adverse event in 7,681 FDA reports for SECUKINUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIARRHOEA accounts for approximately 1.6% of all adverse event reports for SECUKINUMAB, making it a notable side effect.
If you experience diarrhoea while taking SECUKINUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.